We have been working on a drug that effectively puts the foot on the accelerator to rev up the immune system... If we use this with a vaccine we can steer the immune cells and train them to target the cancer.
London, UK (PRWEB UK) 13 August 2013
According to an article published online by the Telegraph this week, scientists at the University of Southampton have developed a new drug that works by increasing the ability of the immune system to recognise and attack tumours. A £5 million European Union funded trial of the new treatment is due to start next year. http://bit.ly/1bm275Q - 11 August 2013
SMi’s keynote speaker at Cancer Vaccines 2013, Prof Martin Glennie, who has led the research at the University of Southampton, said:
“Some cancers are able to switch the immune cells off. We have been working on a drug that effectively puts the foot on the accelerator to rev up the immune system... If we use this with a vaccine we can steer the immune cells and train them to target the cancer.”
Prof. Martin Glennie will be providing delegates at SMi’s 2nd annual Cancer Vaccines conference with a unique insight on anti-cancer immunity. The presentation titled: Developing Antibodies to Stimulate Anti-Cancer Immunity will:
- Discuss the nature of anti-cancer immunity and the ability of the immune system to recognise most types of cancer.
- Explore how antibodies recognising key members of the TNFR super family can stimulate T-cell responses against cancer.
- Show that these immuno stimulating antibodies need to engage Fc receptors in the host to provide sufficient cross-linking of the various TNFR’s.
- Discuss how antibody engineering will be used to optimise cross-linking activity in vivo.
Cancer Vaccines | 18-19 September 2013, London UK
To meet Prof. Martin Glennie and for further information visit the event homepage at: http://www.canervaccinesevent.com